BioLight Life Sciences Ltd (BOLT) — Cash Flow-to-Debt Ratio
BioLight Life Sciences Ltd (BOLT) has a Cash Flow-to-Debt Ratio of -2.45x as of December 2025, meaning its operating cash flow of ILA-5.49 Million could theoretically repay -2% of its total liabilities (ILA2.24 Million) in one year. See financial agility of BioLight Life Sciences Ltd to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
BioLight Life Sciences Ltd Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for BioLight Life Sciences Ltd across 14 annual periods. For the full cash flow conversion analysis, see BioLight Life Sciences Ltd (BOLT) cash conversion ratio.
Annual Cash Flow-to-Debt Ratio for BioLight Life Sciences Ltd (2012–2025)
Year-by-year debt coverage analysis for BioLight Life Sciences Ltd. Check cash flow quality index of BioLight Life Sciences Ltd to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (ILA) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.84x | ILA-10.85 Million | ILA2.24 Million | ▼ -48.8% |
| 2024 | -3.25x | ILA-10.99 Million | ILA3.38 Million | ▼ -7.0% |
| 2023 | -3.04x | ILA-9.58 Million | ILA3.15 Million | ▼ -5.7% |
| 2022 | -2.87x | ILA-9.54 Million | ILA3.32 Million | ▲ +21.0% |
| 2021 | -3.64x | ILA-10.03 Million | ILA2.75 Million | ▼ -50.9% |
| 2020 | -2.41x | ILA-11.39 Million | ILA4.72 Million | ▼ -6.9% |
| 2019 | -2.26x | ILA-15.36 Million | ILA6.80 Million | ▼ -25.9% |
| 2018 | -1.79x | ILA-22.39 Million | ILA12.49 Million | ▼ -18.5% |
| 2017 | -1.51x | ILA-25.32 Million | ILA16.73 Million | ▼ -6.2% |
| 2016 | -1.43x | ILA-26.94 Million | ILA18.90 Million | ▲ +3.9% |
| 2015 | -1.48x | ILA-24.04 Million | ILA16.21 Million | ▲ +19.3% |
| 2014 | -1.84x | ILA-26.99 Million | ILA14.70 Million | ▲ +14.4% |
| 2013 | -2.15x | ILA-26.23 Million | ILA12.22 Million | ▲ +49.8% |
| 2012 | -4.27x | ILA-19.46 Million | ILA4.55 Million | — |